Cholesteryl Ester Transfer Protein Inhibition, High-Density Lipoprotein Raising, and Progression of Coronary Atherosclerosis-Reference-Cited by-同舟云学术

Cholesteryl Ester Transfer Protein Inhibition, High-Density Lipoprotein Raising, and Progression of Coronary Atherosclerosis

Published:2008-12-09 Issue:24 Volume:118 Page:2506-2514
ISSN:0009-7322
Container-title:Circulation
language:en
Short-container-title:Circulation

Author:

Nicholls Stephen J.¹,Tuzcu E. Murat¹,Brennan Danielle M.¹,Tardif Jean-Claude¹,Nissen Steven E.¹

Affiliation:

1. From the Departments of Cardiovascular Medicine (S.J.N., E.M.T., D.M.B., S.E.N.) and Cell Biology (S.J.N.), Cleveland Clinic, Cleveland, Ohio; and Montreal Heart Institute (J.-C.T.), Montreal, Quebec, Canada.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Physiology (medical),Cardiology and Cardiovascular Medicine

Reference50 articles.

1. Effect of Torcetrapib on the Progression of Coronary Atherosclerosis

2. Effect of Torcetrapib on Carotid Atherosclerosis in Familial Hypercholesterolemia

3. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial

4. Effects of Torcetrapib in Patients at High Risk for Coronary Events

5. In interests of patient safety Pfizer stops all torcetrapib clinical trials; company has notified FDA and is in the process of notifying all clinical investigators and other regulatory authorities [press release]. New York NY: Pfizer; December 2 2006.

Cited by 196 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evolving Therapeutic Targets;Clinical Lipidology;2024

2. A new risk factor for coronary artery disease can be detected by an ApoA1 mAb-based assay;Clinica Chimica Acta;2024-01

3. Association of serum cytokines with coronary chronic total occlusion and their role in predicting procedural outcomes;Hellenic Journal of Cardiology;2023-08

4. CETP Inhibitors: Should We Continue to Pursue This Pathway?;Current Atherosclerosis Reports;2022-11-21

5. Apolipoprotein B and Cardiovascular Disease: Biomarker and Potential Therapeutic Target;Metabolites;2021-10-08